Shoulder pain is one of the most common medical problems. In the USA, Kelsey reported in 1982' an incidence of 1 ment showed no significant changes compared with base line (table) .
SALINE GROUP
The diagnoses of the patients who received IA saline were RA (four), OA (one), frozen shoulder (three), and rotator cuff tendonitis (one). The reduction in VASP at the three follow up assessments was 8-4%, 5.90%0, and 16-4% respectively, none of which were significantly different from base line (figure). Again, there was no statistically significant change in range of active movement (table) . Six patients in the saline group subsequently received IA guanethidine at the end of the study. Four of these, who had OA, RA (two), and frozen shoulder, recorded a marked (> 50%) reduction in VASP on the follow up visit two months after the end of the study. The results are not included in the statistical analysis as these patients did not form part of the double blind trial.
Discussion
Guanethidine has been used routinely in the past few years to produce regional blockade of the SNS and relieve the pain of reflex sympathetic dystrophy. This has, in general, been performed as a regional block requiring the application of a proximal tourniquet and administering the drug IV. Our double blind study, the first attempt to investigate the efficacy of an IA injection of guanethidine in the relief of resistant shoulder pain, revealed that guanethidine produced a significant improvement at the two month follow up, which was not seen in the saline group. The level of improvement of VASP in the saline group was within the recognised values for placebo group (up to 30%).l6 It was interesting to note that significant (> 50%) improvement was also seen in four of the six patients who, having failed to respond to placebo, subsequently received IA guanethidine.
A previous study of regional IV guanethidine has shown improvement of their pain in patients with RA.8 The effect of guanethidine is presumed to be mediated largely by the depletion of catecholamines from sympathetic postganglionic efferents. Reduced sympathetic outflow would decrease the direct inflammatory effect of catecholamines and the indirect catecholamine stimulation of unmyelinated peptidergic afferents implicated in the inflammatory process. '7 The fact that all our patients were resistant to IA steroid injection, physiotherapy, and other well known pain relief modalities, made it difficult to compare our results with results of other studies using the previously mentioned modalities. All patients had previously received suprascapular nerve block; we do not know whether this in some way sensitised the patients to respond to guanethidine. The observation of no significant improvement in range of movement in either group was not unexpected, as most of the patients had marked destruction of the shoulder joint radiologically.
The results achieved in this preliminary study suggest that IA guanethidine has a measurable effect in patients with resistant shoulder pain. Despite the relatively small number and heterogenous nature of the patients, a significant improvement was found in the active group and this should be considered encouraging. However, it is clear that a longer term study with a larger number of more homogenous patients is required before the value of this approach can be fully assessed. Whether it is possible to recognise symptoms that indicate SNS involvement, or whether the earlier use of SNS blockade could be more effective, are questions which both require attention. This treatment does, however, appear to offer another option in a group of patients with limited treatment alternatives.
We thank our shoulder clinic nurse, Mrs Kathy Chiswell, for her help throughout the course of this study. This research was sponsored by a grant from the Arthritis and Rheumatism Council, United Kingdom.
